Literature DB >> 15782137

RKIP downregulates B-Raf kinase activity in melanoma cancer cells.

Sungdae Park1, Miranda L Yeung, Sandy Beach, Janiel M Shields, Kam C Yeung.   

Abstract

The Raf-MEK-ERK protein kinase cascade is a highly conserved signaling pathway that is pivotal in relaying environmental cues from the cell surface to the nucleus. Three Raf isoforms, which share great sequence and structure similarities, have been identified in mammalian cells. We have previously identified Raf kinase inhibitor protein (RKIP) as a negative regulator of the Raf-MEK-ERK signaling pathway by specifically binding to the Raf-1 isoform. We show here that RKIP also antagonizes kinase activity of the B-Raf isoform. Yeast two-hybrid and coimmunoprecipitation experiments indicated that RKIP specifically interacted with B-Raf. Ectopic expression of RKIP antagonized the kinase activity of B-Raf. We showed that the effects of RKIP on B-Raf functions were independent of its known inhibitory action on Raf-1. The expression levels of RKIP in melanoma cancer cell lines are low relative to primary melanocytes. Forced expression of RKIP partially reverted the oncogenic B-Raf kinase-transformed melanoma cancer cell line SK-Mel-28. The low expression of RKIP and its antagonistic action on B-Raf suggests that RKIP may play an important role in melanoma turmorgenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15782137     DOI: 10.1038/sj.onc.1208435

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

2.  A computational framework for the topological analysis and targeted disruption of signal transduction networks.

Authors:  Madhukar S Dasika; Anthony Burgard; Costas D Maranas
Journal:  Biophys J       Date:  2006-04-14       Impact factor: 4.033

3.  Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit.

Authors:  Steven Theroux; Mandy Pereira; Kimberly S Casten; Rebecca D Burwell; Kam C Yeung; John M Sedivy; Jan Klysik
Journal:  Brain Res Bull       Date:  2006-12-11       Impact factor: 4.077

4.  Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.

Authors:  S Beach; H Tang; S Park; A S Dhillon; E T Keller; W Kolch; K C Yeung
Journal:  Oncogene       Date:  2007-10-22       Impact factor: 9.867

5.  Cilia movement regulates expression of the Raf-1 kinase inhibitor protein.

Authors:  Kelli M Sas; Michael G Janech; Elizabeth Favre; John M Arthur; P Darwin Bell
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-23

Review 6.  A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics.

Authors:  Yuhao Wang; Benjamin Bonavida
Journal:  Crit Rev Oncog       Date:  2018

7.  Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater.

Authors:  Hyun-Soo Kim; Sun Ho Lee; Kyu Yeoun Won; Gou Young Kim; Yong-Koo Park; Youn Wha Kim
Journal:  Virchows Arch       Date:  2011-11-20       Impact factor: 4.064

8.  Phosphatidylenthanolamine Binding Protein aka Raf Kinase Inhibitor Protein: A Brief History of Its Discovery and the Remarkable Diversity of Biological Functions.

Authors:  John M Sedivy
Journal:  For Immunopathol Dis Therap       Date:  2011

9.  Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma.

Authors:  Swadesh K Das; Sujit K Bhutia; Upneet K Sokhi; Belal Azab; Zhao-Zhong Su; Habib Boukerche; Talha Anwar; Erika L Moen; Devasis Chatterjee; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

10.  Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Authors:  Cindy S Hwang; Victor G Prieto; Abdul H Diwan; Gregory Lizee; Julie A Ellerhorst; Suhendan Ekmekcioglu; Ping Liu; Omar Eton; Sandra A Kinney; Elizabeth A Grimm; Patrick Hwu; Kevin B Kim
Journal:  Melanoma Res       Date:  2008-08       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.